| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Mastrocola Lauren | Principal Accounting Officer | C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON | /s/ Alex Nemiroff, as Attorney-in-Fact | 21 Nov 2025 | 0001827639 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PRAX | Common Stock | Options Exercise | $51,826 | +1,047 | +10% | $49.50 | 11,489 | 20 Nov 2025 | Direct | |
| transaction | PRAX | Common Stock | Options Exercise | $42,596 | +508 | +4.4% | $83.85 | 11,997 | 20 Nov 2025 | Direct | |
| transaction | PRAX | Common Stock | Options Exercise | $208,093 | +1,557 | +13% | $133.65 | 13,554 | 20 Nov 2025 | Direct | |
| transaction | PRAX | Common Stock | Options Exercise | $116,232 | +2,680 | +20% | $43.37 | 16,234 | 20 Nov 2025 | Direct | |
| transaction | PRAX | Common Stock | Options Exercise | $9,191 | +207 | +1.3% | $44.40 | 16,441 | 20 Nov 2025 | Direct | |
| transaction | PRAX | Common Stock | Options Exercise | $104,384 | +2,351 | +14% | $44.40 | 18,792 | 20 Nov 2025 | Direct | |
| transaction | PRAX | Common Stock | Options Exercise | $298,935 | +5,250 | +28% | $56.94 | 24,042 | 20 Nov 2025 | Direct | |
| transaction | PRAX | Common Stock | Sale | $2,198,879 | -11,455 | -48% | $191.96 | 12,587 | 20 Nov 2025 | Direct | F1 |
| transaction | PRAX | Common Stock | Sale | $413,365 | -2,145 | -17% | $192.71 | 10,442 | 20 Nov 2025 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PRAX | Stock Option (Right to Buy) | Options Exercise | $0 | -1,047 | -100% | $0.000000 | 0 | 20 Nov 2025 | Common Stock | 1,047 | $49.50 | Direct | F3 |
| transaction | PRAX | Stock Option (Right to Buy) | Options Exercise | $0 | -508 | -100% | $0.000000 | 0 | 20 Nov 2025 | Common Stock | 508 | $83.85 | Direct | F4 |
| transaction | PRAX | Stock Option (Right to Buy) | Options Exercise | $0 | -1,557 | -100% | $0.000000 | 0 | 20 Nov 2025 | Common Stock | 1,557 | $133.65 | Direct | F5 |
| transaction | PRAX | Stock Option (Right to Buy) | Options Exercise | $0 | -2,680 | -22% | $0.000000 | 9,320 | 20 Nov 2025 | Common Stock | 2,680 | $43.37 | Direct | F6 |
| transaction | PRAX | Stock Option (Right to Buy) | Options Exercise | $0 | -207 | -100% | $0.000000 | 0 | 20 Nov 2025 | Common Stock | 207 | $44.40 | Direct | |
| transaction | PRAX | Stock Option (Right to Buy) | Options Exercise | $0 | -2,351 | -71% | $0.000000 | 981 | 20 Nov 2025 | Common Stock | 2,351 | $44.40 | Direct | F7 |
| transaction | PRAX | Stock Option (Right to Buy) | Options Exercise | $0 | -5,250 | -32% | $0.000000 | 11,376 | 20 Nov 2025 | Common Stock | 5,250 | $56.94 | Direct | F8 |
| Id | Content |
|---|---|
| F1 | The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $191.500 to $192.432. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| F2 | The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $192.552 to $193.109. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. |
| F3 | This option was fully vested as of January 1, 2023. |
| F4 | This option was fully vested as of May 28, 2024. |
| F5 | This option was fully vested as of September 8, 2024. |
| F6 | The shares underlying this stock option vested as to 50% on January 12, 2024 and the remaining 50% vesting over a four-year period, with 25% of such shares vesting on January 12, 2025 and the remaining vesting in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date. |
| F7 | The shares underlying this stock option vested as to 25% on January 12, 2024 and the remaining shares vest in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date. |
| F8 | The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the Reporting Person's continued service through each vesting date. |
The transactions reported in this Form 4 were effected for estate planning purposes.